EUVIMEDEUVIMED entdecken
Crossref

Real-world safety of nemolizumab: A pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS)

Mao-Ling Sun, Si-Wen Wang, Yun-Qiu Gao, Zhi-Yuan Chen, Xin-De Liu, Xing-Hua Gao, Ya-Xin Guo

Journal of the American Academy of Dermatology · 2026-09 · 95 (3) · 882-884

DOI: 10.1016/j.jaad.2026.05.080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-09. Verfasst von Mao-Ling Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Hospital of China Medical University, Shenyang, China; Key Laboratory of Immunodermatology, Ministry of Educatio…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Liaoning Provincial Natural Science Foundation, National Key Research and Development Program of China Stem Cell and Translational Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

FAERSFDA Adverse Event Reporting Systematopic dermatitiscutaneous adverse reactionsnemolizumabpharmacovigilancepost-marketing safety analysisprurigo nodularis

Autor:innen und Institutionen

  • Department of Dermatology, The First Hospital of China Medical University, Shenyang, China; Key Laboratory of Immunodermatology, Ministry of Education, and National Health Commission, National Joint Engineering Research…
  • Department of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, China; Key Laboratory of Precision Prevention and Treatment for Obesity and Metabolic Diseases, China Medical Universi…

Förderung

  • National Key Research and Development Program of China
  • Liaoning Provincial Natural Science Foundation
  • National Key Research and Development Program of China Stem Cell and Translational Research

Zitieren

APA

Sun, M. L., Wang, S. W., Gao, Y. Q., Chen, Z. Y., Liu, X. D., Gao, X. H., & Guo, Y. X. (2026). Real-world safety of nemolizumab: A pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS). Journal of the American Academy of Dermatology, 95(3), 882-884. https://doi.org/10.1016/j.jaad.2026.05.080

Vancouver

Sun ML, Wang SW, Gao YQ, Chen ZY, Liu XD, Gao XH, et al. Real-world safety of nemolizumab: A pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS). Journal of the American Academy of Dermatology. 2026;95(3):882-884. doi:10.1016/j.jaad.2026.05.080

BibTeX
@article{Sun2026,
  author = {Sun, Mao-Ling and Wang, Si-Wen and Gao, Yun-Qiu and Chen, Zhi-Yuan and Liu, Xin-De and Gao, Xing-Hua and Guo, Ya-Xin},
  title = {Real-world safety of nemolizumab: A pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS)},
  journal = {Journal of the American Academy of Dermatology},
  year = {2026},
  volume = {95},
  number = {3},
  pages = {882--884},
  doi = {10.1016/j.jaad.2026.05.080}
}
Kostenlos starten →